STOK

+ Watchlist + Portfolio

Stoke Therapeutics, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $26.01
52-Week Range: $20.32 – $40.22
Market Cap: $1.65B
P/E (TTM): —
EPS (TTM): -3.38
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 4.63
PEG Ratio: —
Return on Equity: -61.10%
Return on Assets: -35.87%
Gross Margin: 100.00%
Operating Margin: -701.65%
Profit Margin: 0.00%
Current Ratio: 7.69
Debt/Equity: 0.01
Total Debt: $2.68M
Free Cash Flow: $-106.20M
Revenue Growth: -32.50%
Earnings Growth: —
Enterprise Value: $1.36B

STOK Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$12.40M	$8.78M	$36.55M	$184.42M
Research & Development	$77.84M	$82.23M	$89.13M	$137.92M
Selling, General & Admin	$38.92M	$41.32M	$48.79M	$67.09M
Operating Expenses	$116.76M	$123.55M	$137.93M	$205.01M
Operating Income	-$104.36M	-$114.77M	-$101.37M	-$20.59M
EBITDA	-$102.81M	-$112.30M	-$99.19M	-$18.82M
Pretax Income	-$101.07M	-$104.70M	-$88.98M	-$6.88M
Net Income	-$101.07M	-$104.70M	-$88.98M	-$6.88M
Diluted EPS	-2.60	-2.38	-1.65	-0.12
Diluted Shares	38.90M	43.99M	54.01M	59.22M

STOK Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$113.56M	$191.44M	$127.98M	$84.22M
Receivables	$588.00K	$64.00K	$2.37M	$7.91M
Current Assets	$244.07M	$215.34M	$232.76M	$305.70M
Total Assets	$256.07M	$228.34M	$271.56M	$418.43M
Current Liabilities	$31.39M	$30.82M	$40.06M	$57.88M
Total Debt	$2.36M	$2.06M	$2.32M	$3.01M
Total Liabilities	$71.22M	$68.78M	$42.53M	$65.98M
Retained Earnings	-$297.15M	-$401.85M	-$490.83M	-$497.71M
Shareholders' Equity	$184.85M	$159.56M	$229.02M	$352.46M
Working Capital	$212.68M	$184.52M	$192.70M	$247.82M

STOK Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$31.87M	-$81.07M	-$86.85M	$45.59M
Capital Expenditure	-$3.96M	-$1.62M	-$203.00K	-$670.00K
Free Cash Flow	-$35.83M	-$82.68M	-$87.05M	$44.91M
Depreciation & Amortisation	$1.55M	$2.47M	$2.18M	$1.77M
Stock-Based Compensation	$22.85M	$25.26M	$27.47M	$32.24M
Investing Cash Flow	-$45.88M	$105.95M	-$107.47M	-$186.81M
Financing Cash Flow	$46.41M	$53.01M	$131.09M	$97.39M
Net Change in Cash	-$31.34M	$77.89M	-$63.23M	-$43.84M

STOK Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$158.57M	$13.82M	$10.63M	$1.40M	$6.23M	$9.32M
Research & Development	$32.68M	$25.86M	$37.70M	$41.70M	$39.67M	$49.50M
Selling, General & Admin	$14.65M	$15.26M	$16.03M	$21.15M	$19.97M	$25.25M
Operating Expenses	$47.33M	$41.12M	$53.72M	$62.84M	$59.65M	$74.75M
Operating Income	$111.24M	-$27.30M	-$43.09M	-$61.44M	-$53.42M	-$65.43M
EBITDA	$111.72M	-$26.85M	-$42.65M	-$61.03M	-$52.98M	-$64.97M
Pretax Income	$114.16M	-$23.48M	-$39.63M	-$57.93M	-$50.00M	-$61.62M
Income Tax	$1.28M	$0.00	-$1.28M	—	$0.00	$0.00
Net Income	$112.88M	-$23.48M	-$38.35M	-$57.93M	-$50.00M	-$61.62M
Diluted EPS	1.90	-0.40	-0.65	—	-0.79	-0.93
Diluted Shares	59.40M	58.35M	58.61M	—	63.06M	66.02M

STOK Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$274.82M	$101.47M	$83.39M	$84.22M	$155.66M	$110.00M
Receivables	$606.00K	$1.62M	$10.84M	$7.91M	$6.14M	$8.72M
Current Assets	$375.74M	$269.97M	$272.44M	$305.70M	$366.68M	$322.54M
Total Assets	$406.89M	$384.51M	$360.26M	$418.43M	$443.28M	$393.97M
Current Liabilities	$44.69M	$38.68M	$41.73M	$57.88M	$40.81M	$41.93M
Total Debt	$2.35M	$2.30M	$2.91M	$3.01M	$2.43M	$1.84M
Total Liabilities	$56.81M	$49.56M	$52.16M	$65.98M	$48.40M	$48.42M
Retained Earnings	-$377.95M	-$401.43M	-$439.78M	-$497.71M	-$547.72M	-$609.34M
Shareholders' Equity	$350.07M	$334.94M	$308.11M	$352.46M	$394.88M	$345.55M
Working Capital	$331.05M	$231.29M	$230.71M	$247.82M	$325.88M	$280.61M

STOK Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$131.83M	-$25.42M	-$30.37M	-$30.45M	-$60.58M	-$56.59M
Capital Expenditure	-$152.00K	-$154.00K	-$132.00K	-$232.00K	-$353.00K	-$1.98M
Free Cash Flow	$131.68M	-$25.58M	-$30.50M	-$30.69M	-$60.94M	-$58.56M
Depreciation & Amortisation	$477.00K	$446.00K	$442.00K	$405.00K	$439.00K	$458.00K
Stock-Based Compensation	$6.75M	$7.60M	$8.04M	$9.85M	$8.75M	$10.80M
Investing Cash Flow	$13.63M	-$148.48M	$9.09M	-$61.06M	$50.69M	$9.02M
Financing Cash Flow	$1.37M	$554.00K	$3.12M	$92.34M	$84.33M	$1.91M
Net Change in Cash	$146.83M	-$173.34M	-$18.15M	$826.00K	$74.44M	-$45.66M

Market Snapshot

About

Stoke Therapeutics, Inc. is a biotechnology company focused on treating severe genetic diseases by precisely upregulating protein expression. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach to develop therapies for diseases caused by haploinsufficiency. Stoke is developing treatments for conditions including Dravet syndrome and autosomal dominant optic atrophy.